Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

Next Previous
Trial Profile

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan (Primary) ; Pazopanib (Primary) ; Temozolomide (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms PAZIT

    • Most Recent Events

    • 24 Jun 2019 Planned number of patients changed from 18 to 32.
    • 06 Mar 2019 Planned End Date changed from 30 Nov 2019 to 30 Jun 2021.
    • 06 Mar 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top